Study guide

6.1 Investigational Product Labeling and Storage

Certified Clinical Research Coordinator CCRC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Scientific Concepts and Research Design

1.1 Protocol Elements 1.2 Study Design and Objectives 1.3 Study Endpoints and Biostatistics

2 Chapter 2: Ethical Principles and Guidelines

2.1 Ethical Principles (Declaration of Helsinki, Belmont Report) 2.2 Informed Consent Process and Documentation 2.3 Vulnerable Populations and Assent

3 Chapter 3: IRB/IEC Oversight and Participant Safety

3.1 IRB/IEC Functions and Oversight 3.2 Adverse Event Classification and Reporting 3.3 Safety Monitoring and Safety Reporting

4 Chapter 4: Participant Rights and Ethics

4.1 Participant Rights and Confidentiality (HIPAA/GDPR) 4.2 Conflicts of Interest 4.3 Ethical Scenarios in Clinical Trials

5 Chapter 5: Product Development and Regulatory Framework

5.1 Drug and Device Development Phases 5.2 U.S. and International Regulatory Frameworks 5.3 Investigational Product Investigator's Brochure (IB)

6 Chapter 6: Investigational Product Accountability

6.1 Investigational Product Labeling and Storage 6.2 Investigational Product Receipt, Dispensing, and Accountability 6.3 Investigational Product Return and Destruction

7 Chapter 7: Regulatory Submissions and Actions

7.1 Regulatory Submissions (IND, NDA, IDE, PMA) 7.2 Regulatory Actions and Compliance 7.3 Pharmacokinetics and Pharmacodynamics in Product Development

8 Chapter 8: Clinical Trial Operations and GCP Principles

8.1 Introduction to ICH E6 GCP Principles (including R3 updates) 8.2 Investigator Responsibilities under GCP 8.3 Sponsor Responsibilities and Oversight

9 Chapter 9: Essential Documents and Site Qualification

9.1 Essential Documents (Pre-study, During, Post-study) 9.2 Site Selection and Qualification 9.3 Quality Management and Standard Operating Procedures (SOPs)

10 Chapter 10: Protocol Deviations and Amendments

10.1 Protocol Adherence and Compliance 10.2 Protocol Deviations and Violations 10.3 Protocol Amendments and Version Control

11 Chapter 11: Monitoring Visits and Audits

11.1 Monitoring Preparation and Visit Types 11.2 Monitoring Visits (SIV, IMV, COV) 11.3 Regulatory Inspections and Site Audits

12 Chapter 12: Study and Site Management - Startup

12.1 Site Startup Operations 12.2 Site Budget and Contract Management 12.3 Site Staffing, Training, and Documentation

13 Chapter 13: Enrollment and Recruitment

13.1 Enrollment Management and Strategies 13.2 Participant Recruitment and Retention 13.3 Participant Compensation and Ethics

14 Chapter 14: Daily Trial Coordination

14.1 Visit Scheduling and Logistics 14.2 Equipment Maintenance and Calibration 14.3 Specimen Handling and Shipping (IATA/dangerous goods)

15 Chapter 15: Quality Improvement and Site Closeout

15.1 Participant Safety Management 15.2 Quality Improvement and Site Audits Preparation 15.3 Study and Site Closeout Procedures

16 Chapter 16: Source Documentation and Case Report Forms

16.1 Source Documentation Standards (ALCOA-C) 16.2 Case Report Forms and eCRF Completion 16.3 Electronic Data Capture (EDC) Systems

17 Chapter 17: Data Management and Queries

17.1 Data Management Processes 17.2 Data Queries and Discrepancy Resolution 17.3 Data Correction and Audit Trails

18 Chapter 18: Data Privacy and Records Retention

18.1 Data Privacy and Confidentiality 18.2 Records Retention and Archiving 18.3 Compliance in Clinical Trial Informatics

6.1 Investigational Product Labeling and Storage

Key Takeaways Explain This Topic AI

Investigational product (IP) labeling must comply with specific regulatory requirements, prominently stating 'Caution: New Drug - Limited by Federal (or United States) law to investigational use.'

Proper IP storage is critical for maintaining the integrity, stability, and safety of the product, requiring continuous temperature monitoring and restricted access.

Temperature excursions must be documented, reported to the sponsor, and the affected IP quarantined until written authorization for use is provided.

The site must maintain an unblinding mechanism (e.g., sealed envelopes, IRT system access) that is securely stored and only accessed in medical emergencies.

Last updated: October 2026

Investigational Product (IP) Labeling Requirements

The labeling of an investigational product (IP) is a fundamental aspect of clinical trial safety and compliance. Unlike commercially available medications, an IP is not yet proven safe and effective for the indication under study. Therefore, regulatory bodies like the FDA and EMA impose strict rules on how these products must be labeled to prevent misuse and ensure that both the research staff and the subjects are fully aware of the product's investigational nature.

Mandatory Label Elements

In the United States, under 21 CFR Part 312, the immediate package of an investigational new drug intended for human use must bear a label with the statement: "Caution: New Drug - Limited by Federal (or United States) law to investigational use."

Beyond this mandatory statement, Good Clinical Practice (GCP) guidelines dictate that IP labels generally include:

The sponsor's name, address, and telephone number.

The pharmaceutical formulation, route of administration, and quantity of dosage units.

The batch or lot number.

The clinical trial reference code or protocol number.

The subject identification number and/or treatment number, where applicable.

Directions for use, or a reference to a patient instruction sheet.

Storage conditions.

The expiration or retest date (though this is sometimes managed via interactive response technology [IRT] systems to allow for expiry updates without relabeling).

  • The phrase "Keep out of reach of children."
  • Blinding and Randomization in Labeling

In blinded trials, the labeling must ensure that the identity of the IP (active vs. placebo) remains concealed. This is typically achieved using identical packaging and labeling for all treatment arms, differentiated only by a unique kit or treatment number. The label must not contain any information that could inadvertently break the blind.

Real-World Example: In a Phase III double-blind trial for a novel oncology drug, both the active drug and the placebo are formulated as visually identical clear liquids in matching vials. The labels on both vials are identical except for the kit number (e.g., Kit #10452 vs. Kit #10453). When the coordinator registers a subject in the IRT system, the system assigns a specific kit number. The coordinator retrieves that exact kit, ensuring the blind is maintained.

IP Storage Conditions and Facility Requirements

The storage of investigational products is critical. An IP that degrades due to improper storage can jeopardize the safety of the subject and the validity of the trial data. The Principal Investigator (PI) is ultimately responsible for IP accountability at the site, which includes ensuring proper storage.

Essential Storage Facility Features

Clinical sites must designate a specific, secure area for IP storage. The key requirements include:

Feature Requirement Purpose

Security Restricted access (e.g., locked room, badge access, locked cabinet). To prevent unauthorized access, theft, or tampering. Only delegated staff should have access.

Environmental Control Ability to maintain the specific temperature, humidity, and light conditions required by the protocol. To preserve the chemical and physical stability of the IP.

Organization Separate areas for different trials, and for IPs of different statuses (e.g., active, quarantined, returned). To prevent cross-contamination or accidental dispensing of the wrong product.

Temperature Monitoring and Logging

Continuous temperature monitoring is the gold standard for IP storage. Depending on the product, storage may require:

Ambient/Room Temperature: Typically 15°C to 25°C (59°F to 77°F).

Refrigerated: Typically 2°C to 8°C (35.6°F to 46.4°F).

Frozen: Often -20°C (-4°F) or ultra-low -70°C to -80°C (-94°F to -112°F).

Sites must use calibrated continuous temperature monitoring devices (data loggers) that record the temperature at regular intervals. A manual min/max thermometer checked daily is often used as a backup, but continuous logs are heavily preferred by sponsors and auditors.

Best Practice: Calibrate temperature monitoring equipment annually or according to the manufacturer's recommendations, and keep the calibration certificates in the site's regulatory binder.

Managing Temperature Excursions

A temperature excursion occurs when the IP is exposed to conditions outside the protocol-specified range. Handling these events correctly is a frequent focus during site monitoring visits and FDA inspections.

The Excursion Workflow

Identify and Quarantine: Immediately upon discovering an excursion (e.g., an alarm sounds, or a data logger shows the fridge hit 9°C for two hours), the affected IP must be physically separated and clearly marked as "QUARANTINED - DO NOT USE."

Document: Download the temperature data and document the highest/lowest temperature reached and the total duration of the excursion.

Report: Notify the sponsor or Contract Research Organization (CRO) immediately, usually by submitting a formal Temperature Excursion Form.

Wait for Disposition: The sponsor will review the stability data for the product and determine if it is still safe to use.

Action: The site must wait for written authorization from the sponsor before either returning the IP to active stock or destroying/returning it.

Never dispense an IP that has experienced an excursion until explicit, written approval from the sponsor is received.

Unblinding Procedures

While maintaining the blind is crucial, there are rare medical emergencies where the treating physician must know what the subject received to provide proper care (e.g., an unexpected severe adverse event that requires specific antidotes).

The protocol will outline the unblinding procedure. Historically, this involved opening a sealed, tamper-evident envelope. Today, it is almost exclusively managed through the IRT system. If an investigator needs to unblind, they log into the system, select the subject, and request unblinding. The system immediately reveals the treatment assignment and generates audit trails notifying the sponsor.

Sites must ensure that all relevant staff are trained on the emergency unblinding procedure and have the necessary access credentials at all times.